Description
Product Description
Toremifene Citrate (CAS 89778-27-8) is a triphenylethylene derivative and selective estrogen receptor modulator (SERM) commonly used in preclinical research to study estrogen receptor (ER) pathways and hormone-dependent cancers. Its high-purity powder form enables precise dosing for in vitro and in vivo assays, making it an essential tool for mechanistic and pharmacological studies.
Mechanistically, Toremifene binds to estrogen receptors (ERα and ERβ), acting as an antagonist in breast and certain reproductive tissues while exhibiting partial agonist activity in bone and cardiovascular tissues. This selective activity allows researchers to study ER-mediated transcriptional regulation, cell proliferation, apoptosis, and estrogen-responsive gene expression.
In preclinical anticancer studies, Toremifene Citrate has been shown to induce cell-cycle arrest, modulate apoptotic pathways, and alter signaling cascades associated with hormone-responsive tumor growth. It is often used in combination with chemotherapeutic agents or targeted therapies to evaluate synergistic or antagonistic effects on cell viability, DNA synthesis, and tumor growth inhibition.
The powder form provides enhanced stability and facilitates incorporation into experimental protocols, including 3D cell culture models, xenograft studies, and high-throughput screening assays. Toremifene Citrate also serves as a reference compound for testing novel ER modulators or investigating resistance mechanisms in breast cancer cells.

Product Specifications
| Parameter | Specification / Data |
|---|---|
| Chemical Name / Synonyms | Toremifene Citrate; 4-[1-(4-chlorophenyl)-2-(4-hydroxyphenyl)ethyl]-phenol citrate; C26H28ClNO.C6H8O7 |
| CAS Number | 89778-27-8 |
| Molecular Formula | C26H28ClNO·C6H8O7 |
| Molecular Weight | 603.93 g/mol |
| Purity / Assay | ≥99% |
| Appearance | White to off-white crystalline powder |
| Dosage Form | Powder for research use |
| Solubility | Soluble in DMSO, ethanol; slightly soluble in water |
| Storage Temperature | 2–8 °C; protect from light |
| Stability | Stable under refrigeration; avoid repeated freeze-thaw cycles |
| Mechanistic Target | Estrogen receptor α/β, ER-mediated transcription, cell-cycle, apoptosis |
| Structural Category | Selective estrogen receptor modulator (SERM), triphenylethylene derivative |
| Applications | Estrogen receptor signaling studies, anticancer research, apoptosis assays, cell-cycle analysis, combination therapy modeling, drug resistance studies |
| Analytical Methods | HPLC, MS, NMR verified; batch consistency confirmed |
| Regulatory Notes | For laboratory research use only |
| Origin | Factory chemical supplier, China; OEM & bulk production available |
| Additional Data | SMILES: CC(C1=CC=C(C=C1)Cl)C2=CC=C(C=C2)C3=CC=C(C=C3)O.C6H8O7; CoA provided for each batch |
Mechanism of Action
Estrogen Receptor Modulation
Toremifene Citrate binds selectively to estrogen receptors (ERα and ERβ), functioning as an antagonist in breast tissue and a partial agonist in other tissues. This allows researchers to investigate tissue-specific ER-mediated transcriptional responses.
Anticancer Activity
Inhibits ER-dependent proliferation in hormone-responsive breast cancer cells
Induces cell-cycle arrest, typically at G0/G1 or S-phase
Activates apoptotic pathways via mitochondrial depolarization, caspase-3/9 activation, and ROS generation
Combination Therapy and Resistance Studies
Evaluates synergistic effects with chemotherapeutics or kinase inhibitors
Studies mechanisms of ER-related drug resistance
Supports high-throughput screening for novel ER modulators
Signal Transduction Impact
Modulates MAPK/ERK and PI3K/AKT signaling pathways
Alters transcription of estrogen-responsive genes
Affects downstream cytotoxicity and proliferation markers

Applications
Preclinical estrogen receptor signaling research
Anticancer drug development and mechanistic studies
Apoptosis and cytotoxicity evaluation in hormone-responsive cells
Cell-cycle and checkpoint analysis
Combination therapy and synergistic effect studies
Resistance mechanism modeling in breast cancer
High-throughput screening for ER modulators
In vivo xenograft tumor studies
Side Effects (Preclinical Observations)
Cellular Effects:
Inhibition of ER-dependent proliferation
Altered gene transcription in estrogen-responsive cells
Modulation of cell-cycle checkpoints
Apoptotic Effects:
Caspase-3 and -9 activation
Mitochondrial depolarization and ROS-mediated stress
Induction of programmed cell death in sensitive cancer cells
Laboratory Handling:
Handle using PPE and fume hood
Avoid inhalation, ingestion, or skin contact
Strictly for laboratory research use
Keywords
Toremifene Citrate, CAS 89778-27-8, powder, selective estrogen receptor modulator, SERM, anticancer research, estrogen receptor signaling, apoptosis studies, cell-cycle analysis, hormone-responsive cancer research, combination therapy evaluation, high-purity research chemical, preclinical oncology reagent, laboratory research reagent, OEM & bulk supply.
Shipping Guarantee
All shipments of Toremifene Citrate powder are securely packaged to protect from moisture and light and shipped via tracked international couriers. Temperature-sensitive packages are handled using cold-chain logistics as needed to ensure compound integrity.
Trade Assurance
≥99% purity confirmed via HPLC, MS, NMR
Batch consistency verified
Certificate of Analysis (CoA) included
OEM & bulk production available
Replacement or refund guaranteed for deviations from specifications
Payment Support
PayPal
Credit Cards (Visa, MasterCard, AmEx)
Bank Transfer (T/T)
USDT / BTC / ETH
Corporate invoicing for bulk orders
Disclaimer
Toremifene Citrate is supplied for laboratory research only. Not for human or veterinary use. Researchers must follow institutional safety protocols. Supplier assumes no liability for misuse.





Reviews
There are no reviews yet.